ACIDIFYING AGENTS --GASTROINTESTINAL ACIDIFYING AGENTS (GUANETHIDINE, RESERPINE, GLUTAMIC ACID HCL, ASCORBIC ACID, FRUIT JUICES, ETC.) LOWER ABSORPTION OF AMPHETAMINES.
URINARY ACIDIFYING AGENTS --(AMMONIUM CHLORIDE, SODIUM ACID PHOSPHATE, ETC.) INCREASE THE CONCENTRATION OF THE IONIZED SPECIES OF THE AMPHETAMINE MOLECULE, THEREBY INCREASING URINARY EXCRETION. BOTH GROUPS OF AGENTS LOWER BLOOD LEVELS AND EFFICACY OF AMPHETAMINES.
ADRENERGIC BLOCKERS --ADRENERGIC BLOCKERS ARE INHIBITED BY AMPHETAMINES. CONCURRENT USE OF BETA-BLOCKERS AND AMPHETAMINES MAY PRODUCE SEVERE HYPERTENSION.
ALKALINIZING AGENTS --GASTROINTESTINAL ALKALINIZING AGENTS (SODIUM BICARBONATE, ETC.) INCREASE ABSORPTION OF AMPHETAMINES. URINARY ALKALINIZING AGENTS (ACETAZOLAMIDE, SOME THIAZIDES) INCREASE THE CONCENTRATION OF THE NON-IONIZED SPECIES OF THE AMPHETAMINE MOLECULE, THEREBY DECREASING URINARY EXCRETION. BOTH GROUPS OF AGENTS INCREASE BLOOD LEVELS AND THEREFORE POTENTIATE THE ACTIONS OF AMPHETAMINES.
ANTIDEPRESSANTS, TRICYCLIC --AMPHETAMINES MAY ENHANCE THE ACTIVITY OF TRICYCLIC OR SYMPATHOMIMETIC AGENTS; D-AMPHETAMINE WITH DESIPRAMINE OR PROTRIPTYLINE AND POSSIBLY OTHER TRICYCLICS CAUSE STRIKING AND SUSTAINED INCREASES IN THE CONCENTRATION OF D-AMPHETAMINE IN THE BRAIN; CARDIOVASCULAR EFFECTS CAN BE POTENTIATED INCLUDING ARRHYTHMIAS.
MAO INHIBITORS --MAOI ANTIDEPRESSANTS, AS WELL AS A METABOLITE OF FURAZOLIDONE, SLOW AMPHETAMINE METABOLISM. THIS SLOWING POTENTIATES AMPHETAMINES, INCREASING THEIR EFFECT ON THE RELEASE OF NOREPINEPHRINE AND OTHER MONOAMINES FROM ADRENERGIC NERVE ENDINGS; THIS CAN CAUSE HEADACHES AND OTHER SIGNS OF HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS AND MALIGNANT HYPERPYREXIA CAN OCCUR, SOMETIMES WITH FATAL RESULTS.
ANTIHISTAMINES --AMPHETAMINES MAY COUNTERACT THE SEDATIVE EFFECT OF ANTIHISTAMINES.
ANTIHYPERTENSIVES --AMPHETAMINES MAY ANTAGONIZE THE HYPOTENSIVE EFFECTS OF ANTIHYPERTENSIVES INCLUDING GUANETHIDINE.
CHLORPROMAZINE --CHLORPROMAZINE BLOCKS DOPAMINE AND NOREPINEPHRINE RECEPTORS, THUS INHIBITING THE CENTRAL STIMULANT EFFECTS OF AMPHETAMINES, AND CAN BE USED TO TREAT AMPHETAMINE POISONING.
ETHOSUXIMIDE --AMPHETAMINES MAY DELAY INTESTINAL ABSORPTION OF ETHOSUXIMIDE.
HALOPERIDOL --HALOPERIDOL BLOCKS DOPAMINE RECEPTORS, THUS INHIBITING THE CENTRAL STIMULANT EFFECTS OF AMPHETAMINES.
LITHIUM CARBONATE --THE ANORECTIC AND STIMULATORY EFFECTS OF AMPHETAMINES MAY BE INHIBITED BY LITHIUM CARBONATE.
MEPERIDINE --AMPHETAMINES POTENTIATE THE ANALGESIC EFFECT OF MEPERIDINE.
METHENAMINE THERAPY --URINARY EXCRETION OF AMPHETAMINES IS INCREASED, AND EFFICACY IS REDUCED, BY ACIDIFYING AGENTS USED IN METHENAMINE THERAPY.
NOREPINEPHRINE --AMPHETAMINES ENHANCE THE ADRENERGIC EFFECT OF NOREPINEPHRINE.
PHENOBARBITAL --AMPHETAMINES MAY DELAY INTESTINAL ABSORPTION OF PHENOBARBITAL; CO-ADMINISTRATION OF PHENOBARBITAL MAY PRODUCE A SYNERGISTIC ANTICONVULSANT ACTION.
PHENYTOIN --AMPHETAMINES MAY DELAY INTESTINAL ABSORPTION OF PHENYTOIN; CO-ADMINISTRATION OF PHENYTOIN MAY PRODUCE A SYNERGISTIC ANTICONVULSANT ACTION.
PROPOXYPHENE --IN CASES OF PROPOXYPHENE OVERDOSAGE, AMPHETAMINE CNS STIMULATION IS POTENTIATED AND FATAL CONVULSIONS CAN OCCUR.
VERATRUM ALKALOIDS --AMPHETAMINES INHIBIT THE HYPOTENSIVE EFFECT OF VERATRUM ALKALOIDS.
CONCURRENT USE OF SYMPATHOMIMETICS WITH VOLATILE LIQUID ANAESTHETICS SUCH AS HALOTHANE MAY INCREASE RISK OF CARDIAC ARRHYTHMIAS.